It’s been a rough quarter for Lion Bioscience. The company’s high-profile CEO Friedrich von Bohlen departed in January as layoffs continued across the firm; it failed to reach its goal of profitability by the end of its fiscal year; and it had to restate its prior-year earnings and revise its future sales outlook. So the company is turning to an old friend in its time of need — the European Bioinformatics Institute, where its flagship product, the SRS data integration system, was originally developed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.